Funding and Research Opportunities

The following funding opportunity announcements from the NHLBI or other components of the National Institutes of Health, might be of interest:

Notices

Notice of Fiscal Policies in Effect for FY 2018
(NOT-OD-18-180) National Institutes of Health

Notice of Legislative Mandates in Effect for FY 2018
(NOT-OD-18-181) National Institutes of Health

Second Round of the NIH Applicant Assistance Program (AAP) for New or Previously Unawarded Small Businesses
(NOT-CA-18-072)
National Cancer Institute
National Heart, Lung, and Blood Institute
National Institute of Neurological Disorders and Stroke

Notice of Frequently Asked Questions for RFA-HL-19-015 "Physician-Scientist (PS) Research Award for Early Stage Investigators (ESIs) (R01 - Clinical Trial Optional)"
(NOT-HL-18-629)
National Heart, Lung, and Blood Institute

Notice of NCATS Participation in RFA-HL-19-018 NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 - Clinical Trial Optional)
(NOT-TR-18-026)
National Center for Advancing Translational Sciences

Requests for Applications

Cardiothoracic Surgical Trials Network (CTSN) Linked Clinical Research Centers (UM1 Clinical Trial Not Allowed )
(RFA-HL-19-009)
National Heart, Lung, and Blood Institute
apply early to allow adequate time to make any corrections to errors found in the application during the submission process by the due date.

Limited Competition: Cardiothoracic Surgical Trials Network (CTSN) Data Coordinating Center (U01 Clinical Trial Required)
(RFA-HL-19-010)
National Heart, Lung, and Blood Institute

NHLBI SBIR Phase IIB Bridge Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 - Clinical Trial Optional)
(RFA-HL-19-017)
National Heart, Lung, and Blood Institute

NHLBI SBIR Phase IIB Small Market Awards to Accelerate the Commercialization of Technologies for Heart, Lung, Blood, and Sleep Disorders and Diseases (R44 Clinical Trial Optional)
(RFA-HL-19-018)
National Heart, Lung, and Blood Institute

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Not Allowed)
(RFA-OD-18-005)
National Heart, Lung, and Blood Institute

Mentored Research Scientist Career Development Award in Tobacco Regulatory Research (K01 - Independent Clinical Trial Required)
(RFA-OD-18-006)
National Heart, Lung, and Blood Institute

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Not Allowed)
(RFA-OD-18-007)
National Heart, Lung, and Blood Institute

Pathway to Independence Award in Tobacco Regulatory Research (K99/R00 - Independent Clinical Trial Required)
(RFA-OD-18-008)
National Heart, Lung, and Blood Institute

Program Announcements

The Mechanistic Role of the Microbiome in the Pathobiology of Heart, Lung, Blood, and Sleep Diseases (R01 - Clinical Trial Not Allowed)
(PA-18-784)
National Heart, Lung, and Blood Institute